Companies To Watch: The hot investment case of AstraZeneca
The medical industry has achieved a new clinical milestone. In what’s touted as a transformational shift in how we approach precision medicine, AstraZeneca released a new study, revealing how its experimental breast cancer pill delayed disease progression by over six months. Join Dan Koh and Emaad Akhtar as they venture into the world of medicine, and analyze what AstraZeneca’s new discovery could mean for its business and cancer treatment moving forward. See omnystudio.com/listener for privacy information.